AI-ACCELERATED DRUG DISCOVERY

Focused On-demand Library for Regulation of nuclear pre-mRNA domain-containing protein 1A

Available from Reaxense
Predicted by Alphafold

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.

We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by our associate Reaxense.

The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.

We utilise our cutting-edge, exclusive workflow to develop focused libraries.

 Fig. 1. The sreening workflow of Receptor.AI

Our methodology employs molecular simulations to explore a wide array of proteins, capturing their dynamic states both individually and within complexes. Through ensemble virtual screening, we address conformational mobility, uncovering binding sites within functional regions and remote allosteric locations. This thorough exploration ensures no potential mechanism of action is overlooked, aiming to discover novel therapeutic targets and lead compounds across an extensive spectrum of biological functions.

Our library distinguishes itself through several key aspects:

  • The Receptor.AI platform integrates all available data about the target protein, including past experiments, literature data, known ligands, structural information and more. This consolidated approach maximises the probability of prioritising highly relevant compounds.
  • The platform uses sophisticated molecular simulations to identify possible binding sites so that the compounds in the focused library are suitable for discovering allosteric inhibitors and the binders for cryptic pockets.
  • The platform integrates over 50 highly customisable AI models, which are thoroughly tested and validated on a multitude of commercial drug discovery programs and research projects. It is designed to be efficient, reliable and accurate. All this power is utilised when producing the focused libraries.
  • In addition to producing the focused libraries, Receptor.AI provides services and end-to-end solutions at every stage of preclinical drug discovery. The pricing model is success-based, which reduces your risks and leverages the mutual benefits of the project's success.

partner

Reaxense

upacc

Q96P16

UPID:

RPR1A_HUMAN

Alternative names:

Cyclin-dependent kinase inhibitor 2B-related protein; p15INK4B-related protein

Alternative UPACC:

Q96P16; A8KA42; B2RBA3; Q7Z5G8; Q96FY9; Q9NVL4

Background:

Regulation of nuclear pre-mRNA domain-containing protein 1A, also known as Cyclin-dependent kinase inhibitor 2B-related protein or p15INK4B-related protein, plays a crucial role in cell cycle regulation. It interacts with the phosphorylated C-terminal heptapeptide repeat domain (CTD) of POLR2A and is involved in the dephosphorylation of the CTD by RPAP2. This protein acts as a negative regulator of cyclin-D1 (CCND1) and cyclin-E (CCNE1), key cyclins in cell cycle progression.

Therapeutic significance:

Understanding the role of Regulation of nuclear pre-mRNA domain-containing protein 1A could open doors to potential therapeutic strategies.

Looking for more information on this library or underlying technology? Fill out the form below and we'll be in touch with all the details you need.
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.